Last $4.65 USD
Change Today -0.01 / -0.21%
Volume 9.7K
CPIX On Other Exchanges
As of 11:23 AM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

cumberland pharmaceuticals (CPIX) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/1/13 - $5.85
52 Week Low
05/8/14 - $4.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

cumberland pharmaceuticals (CPIX) Related Bloomberg News

View More Bloomberg News

cumberland pharmaceuticals (CPIX) Related Businessweek News

No Related Businessweek News Found

cumberland pharmaceuticals (CPIX) Details

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States. The company’s principal products comprise Acetadote, an intravenous formulation of N-acetylcysteine indicated for the treatment of acetaminophen poisoning; Caldolor, an intravenous formulation of ibuprofen for the treatment of pain and fever; and Kristalose, a prescription laxative administered orally for the treatment of constipation. Its products also include Omeclamox-Pak, a triple therapy combination medication for the treatment of Helicobacter pylori infection and duodenal ulcer disease; and Hepatoren injection, which is in Phase II clinical development for the treatment of hepatorenal syndrome. The company markets and sells its products through sales representatives and managers. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

96 Employees
Last Reported Date: 03/11/14
Founded in 1999

cumberland pharmaceuticals (CPIX) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $620.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $297.0K
Chief Development Officer and Senior Vice Pre...
Total Annual Compensation: $392.3K
Chief Commercial Officer, Senior Vice Preside...
Total Annual Compensation: $312.1K
Chief Compliance Officer and Vice President o...
Total Annual Compensation: $227.5K
Compensation as of Fiscal Year 2013.

cumberland pharmaceuticals (CPIX) Key Developments

Cumberland Pharmaceuticals Inc. Enters into a Revolving Credit Loan Agreement with Sun Trust Bank

On June 26, 2014, Cumberland Pharmaceuticals Inc. entered into a revolving credit loan agreement with SunTrust Bank. The loan agreement provides for an aggregate principal amount up to $20 million. It provides an initial revolving line of credit of up to $12 million with the ability for Cumberland to increase the amount to $20 million, under certain conditions. There are no borrowings under the loan agreement and it expires on June 26, 2017. The interest rate is based on a LIBOR pricing grid as referenced in the agreement.

Cumberland Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Cumberland Pharmaceuticals Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the three months ended March 31, 2014, net revenues were $8.1 million, compared to $10.3 million for the prior year period. The change in net Revenue was driven by a decrease in Acetadote(R) revenues, partially offset by increased revenues from Kristalose(R) and Caldolor(R) and the addition of new revenues from Omeclamox-Pak and Vaprisol. Net income attributable to common shareholders for the three months ended March 31, 2014, was $0.3 million, or $0.02 per diluted share, compared to $0.9 million or $0.05 per diluted share during the prior period. However, first quarter net income represented a return to profitability for the Company and an increase from a net loss of $1.5 million or $0.08 per diluted share in the fourth quarter of 2013. Net cash provided by operating activities for the three months ended March 31, 2014, were $982,572, compared to $1,670,651, for the prior year period. Operating income was $408,051 against $1,326,051 a year ago. Income before income taxes was $463,191 against $1,400,693 a year ago. Additions to property and equipment was $29,760 against $60,911 a year ago.

Cumberland Pharmaceuticals and Gloria Pharmaceuticals Announce Joint Research & Development Investment

Cumberland Pharmaceuticals Inc.and China's Gloria Pharmaceuticals Co. announced a joint research & development initiative. Each company has made a $1 million investment in Cumberland Emerging Technologies (CET), which is majority owned by Cumberland and partners with academic research centers to develop promising biopharmaceutical technologies. The new funds will be used to accelerate development of CET's pipeline of new product candidates emerging from Vanderbilt University and other regional research centers. CET was established among Cumberland Pharmaceuticals, Vanderbilt University and the state of Tennessee to support the development of biopharmaceutical product candidates. Gloria will have the first opportunity to negotiate a license to CET products for China, and Cumberland will retain access to CET's product rights for the rest of the world.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPIX:US $4.65 USD -0.01

CPIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Durect Corp $1.50 USD -0.01
Ironwood Pharmaceuticals Inc $15.15 USD -0.25
Lannett Co Inc $36.90 USD +0.18
Pacira Pharmaceuticals Inc/DE $85.27 USD -1.46
Sucampo Pharmaceuticals Inc $6.16 USD -0.0911
View Industry Companies

Industry Analysis


Industry Average

Valuation CPIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.8x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CUMBERLAND PHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at